GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioNTech (BNTX) shares

Learn how to easily invest in BioNTech shares.

BioNTech SE is a biotechnology business based in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. BioNTech employs 2,500 staff and has a trailing 12-month revenue of around USD$7.8 billion.

How to buy shares in BioNTech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BNTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted BioNTech's stock price?

Since the stock market crash in March caused by coronavirus, BioNTech's stock price has had significant positive movement.

Its last market close was $247.68, which is 86.94% up on its pre-crash value of $32.35 and 784.57% up on the lowest point reached during the March crash when the stocks fell as low as $28.

If you had bought $1,000 worth of BioNTech stocks at the start of February 2020, those stocks would have been worth $1,695.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $8,183.35.

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioNTech shares at a glance

Information last updated 2021-10-16.
Latest market close$247.68
52-week range$75.35 - $464.00
50-day moving average $307.93
200-day moving average $251.12
Wall St. target price$341.18
PE ratio 13.8253
Dividend yield N/A (0%)
Earnings per share (TTM) $17.92

BioNTech stock price (NASDAQ: BNTX)

Use our graph to track the performance of BNTX stocks over time.

BioNTech price performance over time

Historical closes compared with the close of $247.68 from 2021-10-15

1 week (2021-10-07) N/A
1 month (2021-09-16) -33.54%
3 months (2021-07-17) 12.03%
6 months (2021-04-16) 63.44%
1 year (2020-10-16) 163.24%
2 years (2019-10-18) 1,651.63%
3 years (2018-10-14) N/A
5 years (2016-10-14) N/A

Is BioNTech under- or over-valued?

Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioNTech's P/E ratio

BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, BioNTech shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

BioNTech's PEG ratio

BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0451. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioNTech's EBITDA

BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.6 billion.

The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.

BioNTech financials

Revenue TTM $7.8 billion
Operating margin TTM 71.2%
Gross profit TTM $-222,037,000
Return on assets TTM 68.31%
Return on equity TTM 133.85%
Profit margin 52.41%
Book value $22.47
Market capitalisation $60.1 billion

TTM: trailing 12 months

Shorting BioNTech shares

There are currently 2.3 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 2.6% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.

BioNTech's "short interest ratio" (SIR)

BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 3.2 million). BioNTech's SIR currently stands at 0.71. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 710 shares are currently held short.

However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 10 shares are currently held short) or 0.0294% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.

BioNTech share dividends

We're not expecting BioNTech to pay a dividend over the next 12 months.

BioNTech share price volatility

Over the last 12 months, BioNTech's shares have ranged in value from as little as $75.345 up to $464. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -1.1645. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site